Xintela AB

📍 Lund, Sweden🗓 Founded 2009👥 25 employees💰 Last funded Sep 2014
Biotechnology Research🌐 xintela.se
Website LinkedIn
Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2009
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Sweden
1
United Kingdom
1
Frequently asked questions
Who invested in Xintela AB?
Xintela AB has 2 investors on record on gritt.io, 2 mid-stage.
When did Xintela AB last raise funding?
The most recent investment in Xintela AB recorded on gritt.io was in September 2014.
When was Xintela AB founded?
Xintela AB was founded in 2009.
What industry is Xintela AB in?
Xintela AB operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Xintela AB based?
Xintela AB is headquartered in Lund, Sweden.